Evergreen Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Evergreen Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$39.6K	Hold	16,915	–	–	﹤0.01%	1498
2025 Q4	$22.8K	Hold	16,915	–	–	﹤0.01%	1413
2025 Q3	$25.5K	Hold	16,915	–	–	﹤0.01%	1314
2025 Q2	$19.6K	Hold	16,915	–	–	﹤0.01%	1130
2025 Q1	$26.9K	Hold	16,915	–	–	﹤0.01%	1087
2024 Q4	$51.3K	Hold	16,915	–	–	﹤0.01%	1058
2024 Q3	$62.2K	Hold	16,915	–	–	﹤0.01%	991
2024 Q2	$69.2K	Sell	16,915 -98	-0.6%	-$1.09K	﹤0.01%	931
2024 Q1	$268K	Buy	17,013 +98	+0.6%	+$1.35K	0.01%	676
2023 Q4	$256K	Hold	16,915	–	–	0.01%	665
2023 Q3	$339K	Hold	16,915	–	–	0.01%	513
2023 Q2	$477K	Hold	16,915	–	–	0.02%	403
2023 Q1	$291K	Hold	16,915	–	–	0.01%	522
2022 Q4	$341K	Hold	16,915	–	–	0.02%	449
2022 Q3	$366K	Buy	+16,915	New	+$463K	0.02%	401

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Evergreen Capital Management's ZNTL Position: Q1 2026 in Review

Evergreen Capital Management held its Zentalis Pharmaceuticals (ZNTL) position steady in Q1 2026 at 16,915 shares worth $39.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1498.

Evergreen Capital Management first reported a position in ZNTL in Q3 2022 and has held it in 15 quarters since. The position peaked at $477K in Q2 2023. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

Evergreen Capital Management held 16,915 shares of Zentalis Pharmaceuticals worth $39.6K as of Q1 2026.
Evergreen Capital Management left its Zentalis Pharmaceuticals share count unchanged in Q1 2026.
Zentalis Pharmaceuticals made up ﹤0.01% of Evergreen Capital Management's portfolio in Q1 2026, its #1498 holding.
Evergreen Capital Management first reported a position in Zentalis Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
Evergreen Capital Management's Zentalis Pharmaceuticals position peaked at $477K in Q2 2023.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Evergreen Capital Management's 13F filing for Q1 2026, filed 14 May 2026.